DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.00 Consensus Target Price from Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been given an average recommendation of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $12.00.

A number of equities research analysts have weighed in on DMAC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC opened at $6.75 on Friday. The stock has a fifty day moving average price of $6.60 and a 200 day moving average price of $6.96. DiaMedica Therapeutics has a 1-year low of $4.39 and a 1-year high of $10.42. The company has a market cap of $363.69 million, a PE ratio of -9.51 and a beta of 1.01.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Analysts anticipate that DiaMedica Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of DiaMedica Therapeutics during the 3rd quarter valued at approximately $8,157,000. Geode Capital Management LLC boosted its stake in shares of DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after acquiring an additional 314,407 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after acquiring an additional 154,701 shares during the period. State Street Corp grew its holdings in shares of DiaMedica Therapeutics by 31.7% in the 4th quarter. State Street Corp now owns 627,771 shares of the company’s stock worth $4,997,000 after acquiring an additional 151,188 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in DiaMedica Therapeutics in the 2nd quarter valued at approximately $829,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical?stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein?kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.